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Alternative splicing is a major mechanism of control-
ling gene expression and protein diversity in higher
eukaryotes. We report that the splicing factor
SRSF10 functions during striated muscle develop-
ment, myoblast differentiation, and glucose pro-
duction both in cells and in mice. A combination of
RNA-sequencing and molecular analysis allowed us
to identify muscle-specific splicing events controlled
by SRSF10 that are critically involved in striatedmus-
cle development. Inclusion of alternative exons 16
and 17 of Lrrfip1 is a muscle-specific event that is
activated by SRSF10 and essential for myoblast dif-
ferentiation. On the other hand, in mouse primary
hepatocytes, PGC1a is a key target of SRSF10 that
regulates glucose production by fasting. SRSF10 re-
presses inclusion of PGC1a exon 7a and facilitates
the production of functional protein. The results high-
light the biological significance of SRSF10 and regu-
lated alternative splicing in vivo.INTRODUCTION
Alternative splicing (AS) is a major mechanism of controlling
gene expression and protein diversity in higher eukaryotes.
Approximately 95% of human multi-exon genes undergo AS
regulation before formingmature mRNA isoforms, andmany iso-
forms are expressed in a cell-type-specific manner (Pan et al.,
2008; Wang et al., 2008). Increasing amount of evidence indi-
cates that precise regulation of AS is responsible for determina-
tion of tissue type and developmental stages, while defects of
splicing pathway or aberrant splicing isoforms have been linked
to various human diseases (Cieply and Carstens, 2015; Xiong
et al., 2015).
AS process is strictly regulated by trans-acting splicing fac-
tors and cis-regulatory RNA elements located within alternative
exons and/or flanking introns (Chen and Manley, 2009; WahlCell Repet al., 2009). The majority of splicing factors are RNA-binding
proteins that can bind to cis elements and interact with each
other or with other auxiliary splicing factors to guide the pro-
duction of splicing isoforms (Fu and Ares, 2014). The most
extensively characterized splicing factors are members of SR
and hnRNP families that have been shown to activate or
repress splice site selection. The outcome of splicing is mainly
determined by the balance of cooperation and competition
among SR proteins, hnRNP proteins, or other regulatory pro-
teins in vivo (Pandit et al., 2013). Many splicing factors are
ubiquitously expressed, while only a few identified so far are
tissue restricted.
Splicing factors and their regulated AS events play important
roles in living cells and organisms. Knockout of many splicing
factor genes in mouse results in multi-organ dysfunction
accompanied by unusual AS changes. Targeted inactivation
of SRSF1 affects splicing transition of the CaMKIId pre-mRNA
during postnatal heart remodeling, causing severe excitation-
contraction coupling defects in mice heart (Xu et al., 2005).
SRSF3 and Slu7 have been shown to regulate liver-specific
AS events, and their expression is essential for liver homeosta-
sis and hepatic metabolism (Elizalde et al., 2014; Sen et al.,
2013). RBM24 is a major muscle-specific splicing regulator,
while its depletion in mice disrupts sarcomerogenesis in striated
muscles (Yang et al., 2014). These findings strongly indicate
that splicing factors play defined roles in specific cells or
tissues.
SRSF10 is a member of the SR protein family that acts as a
sequence-dependent splicing regulator (Feng et al., 2008;
Feng et al., 2009). RNA sequencing (RNA-seq) analysis of
SRSF10-regulated exons in DT40 cells and MEF cells indicated
that SRSF10 can function both positively and negatively in regu-
lating exon inclusion (Li et al., 2014; Zhou et al., 2014b). This
property is likely dependent on its binding locations within the
pre-mRNA relative to the alternative exon. SRSF10 binding
within the alternative exon is associated with activation, while
SRSF10 binding in the region of the flanking constitutive exon
is associated with repression of the alternative exon. Such posi-
tion-dependent activity has been shown previously for a number
of alternative exons regulated by SRSF10, such as activation oforts 13, 1647–1657, November 24, 2015 ª2015 The Authors 1647
Figure 1. Alternative Splicing Analysis in
SRSF10 KO Ventricles
(A) Transverse sections of SRSF10 WT and KO
hearts at embryonic day 13.5 (E13.5) were stained
with H&E. A high-power view of ventricle walls from
WT and KO hearts is shown. Scale bars, 10 mm.
(B) RNA was extracted from WT or KO heart ven-
tricles at E13.5. Relative mRNA levels of indicated
development marker genes were determined by
real-time PCR and normalized to 36b4 mRNA.
Values shown are the mean ± SD, n = 3.
(C) Top six biological function terms for genes
differentially spliced in SRSF10 KO ventricles.
(D) Representative AS events regulated by SRSF10
in E13.5 heart ventricles. Each case is schemati-
cally diagrammed with mapped RNA-seq reads
that cover the corresponding exons (left panels).
White box, flanking consitutive exons; gray box,
alternative exons; black line, introns. The primer
pairs used for RT-PCR are indicated by arrows.
Quantification of the PCR products are measured
as the inclusion/total (In/All) ratio, as shown in the
top right histogram. Values are mean ± SD, n = 3.
The significance of each detected change was
evaluated by Student’s t test.Bclaf1 30 alternative exon inclusion during tumorigenesis (Zhou
et al., 2014a) or repression of Lipin1 cassette exon inclusion dur-
ing adipogenesis (Li et al., 2014).
We previously showed that SRSF10 knockout (KO) mice die of
multiple cardiac defects and degenerative livers in a time win-
dow from mid-gestation until birth (Feng et al., 2009). In that
study, we characterized the mechanism by which SRSF10 con-
trols AS of the pre-mRNA encoding cardiac triadin. Our findings
suggested that the deregulated triadin splicing due to SRSF10
deficiency might be involved in defects in calcium handling in
isolated cardiomyocytes. In this report, we first intended to
investigate AS events regulated by SRSF10 in cardiac muscle.
To this end, we used a RNA-seq approach to identify AS
changes affected by SRSF10 depletion by analyzing the RNA
samples isolated from KO and wild-type (WT) ventricles at em-
bryonic day 13.5 (E13.5). We then examined those validated
AS events in mutant skeletal muscle (E18.5), SRSF10-depleted
mouse myoblast (C2C12) cells, and SRSF10-depleted mouse
primary hepatocytes. Significantly, we identified Lrrfip1 as one
of key splicing targets of SRSF10 in cardiac and skeletal muscle.
We observed that inclusion of Lrrfip1 exons 16 and 17 was mus-
cle specific, which was significantly increased during mouse
heart development and in the myogenic differentiation of
C2C12 cells. Mechanistically, we demonstrated that SRSF10
specifically binds to these two alternative exons in vitro and
in vivo and activates their inclusion. Functionally, specific knock-
down against Lrrfip1 exons 16 and 17 greatly decreased
myogenic differentiation of C2C12 cells, which is comparable
to the effects observed upon SRSF10 knockdown in these cells.
On the other hand, we observed that SRSF10 knockdown signif-
icantly decreased glucose production both in mouse primary he-
patocytes and in mice, especially during fasting conditions. We
identify PGC1a as a key splicing target of SRSF10 for gluconeo-
genesis, which is well known to play critical roles in regulation of1648 Cell Reports 13, 1647–1657, November 24, 2015 ª2015 The Auglucose production by fasting. SRSF10 specifically binds to the
constitutive exon 7 and thereby represses alternative exon 7a in-
clusion of PGC1a pre-mRNA splicing.
Together, these results strongly highlight the biological signif-
icance of the splicing factor SRSF10 and its regulated AS events
in muscle development, differentiation, and glucose production
both in hepatocytes and in mice.
RESULTS
Global Analysis of AS Events in SRSF10 KO Ventricles
We previously observed that SRSF10 KO mice display an undif-
ferentiated and disorganized myocardium at E14.5 (Feng et al.,
2009). This phenotype was again observed in the KO mice
early (at E13.5) (Figure 1A). This indicated that SRSF10 depletion
might affect ventricular myocardium development in mice.
We first examined expression levels of cardiac marker genes
in KO ventricles at E13.5 by real-time RT-PCR. As shown in
Figure 1B, a significant reduction in expression of Myh7,
Myoglobin, cTnT, and Tnnc1 was observed in KO hearts
compared to WT controls. Next, we took advantage of an
RNA-seq platform to determine the role of SRSF10 in the regu-
lation of AS events in murine ventricular myocardium. We had
previously used this approach successfully with other cells to
characterize the biological significance of SRSF10 as a
sequence-specific splicing regulator in vivo (Li et al., 2014;
Zhou et al., 2014a, 2014b).
In brief, total RNAwas extracted fromSRSF10KOandWT em-
bryonic ventricles and then prepared separately for cDNA li-
braries and sequenced using Illumina HiSeq instrument. The
clean reads were aligned against the mouse genome sequence
(GRCm38.fa) and annotated genes (GRCm38.71.gtf). After map-
ping,8,341,394WT (18.5%) and8,300,801 KO (18.0%) reads
were mapped on splice junctions (Table S1). We then usedthors
Figure 2. Examination of AS Events Altered
in SRSF10 KO Skeletal Muscle
(A) H&E staining was performed with transverse
sections of hindlimbs fromWT or SRSF10 KOmice
at E18.5. A high-power view of red squares in up-
per panels is shown in the lower panels. Scale bars
represent 50 mm for the upper panels and 10 mm for
the lower panels.
(B) Transverse sectional areas of individual my-
ofibers were quantitated by using ImageJ soft-
ware. More than 200 individual myofibers were
counted in each group.
(C) Representative AS events identified in SRSF10
KO skeletal muscle. Bar graphs show the ratio of
In/All. Values are mean ± SD, n = 3. The signifi-
cance of each detected change was evaluated
using the Student’s t test.Alternative Splicing Detector (ASD) software, which was used in
our previous studies, to identify SRSF10-regulated AS events
(Zhou et al., 2014b). From a total number of 13,336 splicing
events, we identified 165 AS events that changed significantly
in the KO samples (Table S2). The majority of affected splicing
events belong to the category of cassette exon; the remaining
events fall into other splicing modes. We then subjected these
165 potential events to ontology analysis, and the results re-
vealed that the top three terms are muscle contraction, estab-
lishment of organelle localization, and striated muscle cell
differentiation (Figure 1C).
To validate potential AS events regulated by SRSF10, we de-
signed primers pairs detecting alternative exons in ASD-predi-
cated target genes and used them to analyze RNAs isolated
from WT and KO ventricles by RT-PCR. Of 35 target genes
analyzed, 15 revealed significant differences between WT and
KO samples (Figures 1D and S1). Representative RT-PCR re-
sults of validated splicing events are shown in Figure 1D. Quan-
tification of their RNA products was measured as inclusion/total
(In/All) ratio. Specifically, alternative-exon-containing mRNA iso-
forms were predominantly expressed in WT ventricles for Fxr1,
Lrrfip1, Mef2a, and NASP transcripts; SRSF10 depletion signif-
icantly decreased exon inclusion to a large extent for each
target (Figure 1D). Interestingly, the variant containing exons
15 and 16 of Fxr1, which was identified as a muscle-specific
isoform and necessary for muscle differentiation (Davidovic
et al., 2013), was reduced in KO ventricles. Mef2a is a transcrip-
tion factor essential for myocyte differentiation. Inclusion of
Mef2a exon 9, selectively observed in brain, heart, and skeletal
muscle (Zhu et al., 2005), was greatly decreased in the KO sam-
ples. These results suggested that SRSF10 controls cardiac
muscle development, probably by regulating muscle-specific
AS events.Cell Reports 13, 1647–1657, NoSRSF10 Regulated Alternative
Splicing in Skeletal Muscle
Given that striated muscle cell differentia-
tion was enriched among the affected
splicing genes in ventricles (Figure 1C),we
sought to determine whether SRSF10
plays a pivotal role in the developmentof skeletal muscle, another type of striated muscle. To this
end, transverse sections of hindlimbs were generated from
E18.5 WT and SRSF10 KO embryos and examined using H&E
staining. While WT skeletal muscle fibers show a regular
compact pattern, KOmyofibers are abnormally loose (Figure 2A).
The cross-sectional area of skeletal muscle fibers is significantly
smaller in KO mice than in WT controls (Figure 2B). RT-PCR re-
vealed that the expression levels of myogenic marker genes
were significantly reduced, especially for MyHC and Myf5 (Fig-
ure S2A). These data indicate that lack of SRSF10 also impairs
the development of skeletal muscles.
Next, we used RT-PCR to determine whether the above 15
validated AS events detected in the mutant ventricles were
altered in the mutant skeletal muscle. As shown in Figures 2C
and S2B, 9 of 15 events displays a similar splicing pattern in
KO skeletal muscle as in KO ventricles, especially for inclusion
of Fxr1 exons 15 and 16, Lrrfip1 exons 16 and 17, or Mef2a
exon 9. In addition, we examined expression patterns of other
splicing events that are known to be switched during myoblast
differentiation. For example, inclusion ofCapzb exon 9, a striated
muscle-specific exon (Schafer et al., 1994), is attenuated in
SRSF10 KO skeletal muscles (Figure 2C). The above results
demonstrate that SRSF10 is also involved in skeletal muscle
development and regulates the AS transition during this process.
SRSF10 Knockdown Impairs Myoblast Differentiation
MouseC2C12 is an immortalizedmyoblast cell line and an excel-
lent model for studying skeletal muscle differentiation in vitro. To
further characterize the role of SRSF10 during myogenesis, we
performed a short hairpin RNA (shRNA)-mediated knockdown
assay in C2C12 myoblasts and got two stable cell lines. Knock-
down of SRSF10 dramatically impairs C2C12 differentiation,
as indicated by decreased myotube formation in differentiatedvember 24, 2015 ª2015 The Authors 1649
Figure 3. SRFS10 Knockdown Inhibits Dif-
ferentiation of C2C12 Myoblasts Accompa-
nied with Changed AS Events
(A) C2C12 cells were infected with retroviruses
expressing either SRSF10-specific shRNA
(shSRSF10) or luciferase-shRNA (shLuci) and then
selected for puromycin resistance. Stable cells
were induced to differentiation after transferring to
low horse serum medium and immunostained for
MyHC (green) and DAPI (blue) at the fifth day after
induction.
(B) Differentiation index and fusion index were
measured at the fifth day after induction for dif-
ferentiation. The differentiation index was calcu-
lated as the percentage of total MyHC-positive
cells, and the fusion index was calculated as the
percentage of total nuclei residing in cells con-
taining three or more nuclei.
(C) RNA was extracted from shSRSF10 or shLuci
C2C12 stable cells on the fifth day of differentia-
tion, and relative mRNA levels of skeletal muscle
differentiation markers were determined as in
Figure 1B.
(D) Identification of AS events altered in SRSF10-
depleted C2C12 cells on the fifth day of differen-
tiation. Bar graphs show the ratio of In/All.
All values are mean ± SD, n = 3. The significance of
each detected changewas evaluated by Student’s
t test.shSRSF10-1 and shSRSF10-2 cell lines, compared to shLuci
control cells (Figure 3A). Both the differentiation index and the
fusion index are significantly reduced (Figure 3B). We also
observed a decrease in expression of myogenic differentiation
marker genes in SRSF10 inactivated myoblasts (Figure 3C).
These results demonstrate that SRSF10 is required for C2C12
differentiation in vitro.
Subsequently, we repeated the analysis of all the 16 splicing
events, which have been validated in ventricles and skeletal
muscle, in differentiated shSRSF10 C2C12 myoblasts and con-
trol cells. Ten splicing events are significantly affected by
SRSF10 knockdown (Figures 3D and S3). Similar to the altered
splicing patterns in KO skeletal muscle, loss of SRSF10 signifi-
cantly decreases inclusion rate of Capzb exon 9, Fxr1 exons
15 and 16, or Lrrfip1 exons 16 and 17 in the differentiated myo-
blasts (Figure 3D).
The Variant Containing Lrrfip1 Exons 16 and 17 Is a
Striated-Muscle-Specific Isoform
Among the validated splicing events in ventricles, skeletal mus-
cle, and differentiated C2C12 cells, several splicing changes
have been detected in other cell lines in response to SRSF10
knockdown (e.g., for alternative exon 5a ofBclaf1 and alternative
exon 36 of Ktn1; Zhou et al., 2014a). Others are only detected in
striated muscle or differentiated C2C12 cells. Inclusion of exons
15 and 16 of Fxr1, exons 16 and 17 of lrrfip1, and exon 9 ofMef2a
are specifically regulated in striated muscle tissues or C2C12
cells. Both Fxr1 and Mef2a are well known to be important reg-
ulators for myogenesis (Davidovic et al., 2013; Kaushal et al.,
1994). Lrrfip1 has been identified as a transcriptional repressor
that plays a role in immune response in other cell types (Yang1650 Cell Reports 13, 1647–1657, November 24, 2015 ª2015 The Auet al., 2010); however, the role of the variant including exons
16 and 17 of Lrrfip1 has not been investigated in muscle devel-
opment or differentiation.
For simplicity, we designated the splicing variant composing
of exons 16 and 17 as Lrrfip1a and the excluded one as Lrrfip1b
(Figure 4A). As shown in Figure 4B, Lrrfip1a is the predominant
isoform both in embryonic hearts (lanes 1, 3, and 5) and in post-
natal hearts (lanes 7–10), whereas Lrrfip1b is expressed at
extremely low levels (lanes 1, 3, 5, and 7–10). Upon SRSF10
depletion, the shift in AS results in greatly diminished levels of
Lrrfip1a and an increase in Lrrfip1b (Figure 4B, compare lanes
2, 4, and 6 with lanes 1, 3, and 5). The inclusion rate of exons
16 and 17 is gradually increased during myoblast differentiation
(Figure 4C, compare lanes 2–6 with lane 1; and Figure 4D,
compare lane 1 with lane 3), while Lrrfip1b is the only detectable
isoform in undifferentiated cells in which SRSF10 knockdown
has no effects on its splicing (Figure 4D, compare lane 4 with
lane 2). Interestingly, Lrrfip1a was only examined in hearts and
skeletal muscle among eight different mouse tissues, likely indi-
cating that it is a striated-muscle-specific isoform (Figure 4E,
compare lanes 1 and 2 with lanes 3–8).
To determine whether regulation of exons 16 and 17 inclusion
by SRSF10 was direct, we tested whether SRSF10 could bind to
exon 16/exon17 RNA. Gel-shift assay revealed that SRSF10
intensively binds to both exon 16 and exon 17 RNA in a dose-
dependent manner (Figure 4F). To further measure whether
SRSF10 binds to exon 16/17 mRNA in vivo, we transiently over-
expressed hemagglutinin (HA)-tagged SRSF10 cDNA in NIH 3T3
cells (Figure 4G). In vivo crosslinking followed by immunoprecip-
itation (CLIP) was performed and then RT-PCR analysis was car-
ried out with primer pairs specific for either exon 16 or exon 17thors
Figure 4. Inclusion of Lrrfip1 Exons 16 and 17 Is Muscle Specific and Regulated by SRSF10
(A) Diagrams of Lrrfip1 splicing isoforms. The isoform containing exons 16 and 17 was designated as Lrrfip1a, and the other lacking exons 16 and 17 was
designated as Lrrfip1b.
(B,C, and E) Inclusion of Lrrfip1 exons 16 and 17 was monitored by using RT-PCR in indicated embryonic hearts and postnatal hearts (B), during differentiation of
C2C12 myoblasts (C), and among eight mouse tissues (D). RNA was extracted from E13.5, E15.5, or E18.5 embryonic ventricles of WT and SRSF10 KO mutant
mice, respectively. RNAwas extracted from postnatal WT heart ventricles at the indicated times. Tissue RNAwas extracted from the indicated tissues of 8-week-
old mice. RNA from C2C12 myoblasts was collected at the indicated differentiation time points from day 0 to day 5. 36B4 was used as a loading control.
(D) RNAs were extracted from shLuci or shSRSF10 myoblasts before and on the fifth day of differentiation. Lrrfip1a/b mRNA was measured by RT-PCR.
(F) Indicated 32P-labeled Lrrfip1 exon 16 or 17 RNAs were incubated with increasing amounts of recombinant His-SRSF10 (250 and 500 ng), and complexes were
resolved by nondenaturing PAGE.
(G) NIH 3T3 cells were transiently transfected with HA-tagged SRSF10 or empty-vector controls. Western blotting analysis was performed to confirm the
expression of SRSF10 in cells.
(H) UV cross-RNA immunoprecipitation (CLIP) products from transfected cells (G) were analyzed by RT-PCR with primer pairs complementary to mouse Lrrfip1
exons 16 and 17.(Figure 4H). Consistent with the above gel-shift results, SRSF10
specifically bound to exon 16 and 17 RNA when compared to
empty-vector control (Figure 4H, compare lane 4 and lane 3).
In addition, we constructed the minigene plasmid in which the
genomic DNA fragment of Lrrfip1 exons 15–18 containing the
complete intervening intronic sequences was driven under
the control of the cytomegalovirus (CMV) promoter and followed
by a poly(A) site (Figure S4A). After transfection and total RNA
extraction, RT-PCR analysis revealed that splicing isoform con-
taining exons 16 and 17 was decreased in the SRSF10-depleted
cells and obviously increased in SRSF10-overexpressed cells
(Figures S4B and S4C). Together, these findings are fully in line
with the proposed activation model for SRSF10 (Zhou et al.,
2014b) and strongly suggested that inclusion of exons 16 and
17 of Lrrfip1 was directly regulated by SRSF10.Cell RepLrrfip1a Is Required for Myoblast Differentiation
Given that Lrrfip1a is the muscle-specific isoform of Lrrfip1, we
speculated Lrrfip1a played an important role during myogenic
differentiation. To investigate the role of Lrrfip1a during myoblast
differentiation, we packed two distinct shRNAs designed specif-
ically against Lrrfip1a in retrovirus and delivered recombinant
virus to C2C12 cells. Following selection with puromycin, the
cells were cultured to confluence and subjected to differentia-
tion. While expression of Lrrfip1b was not affected (Figure 5A,
compare lanes 2 and 3 with lane 1), the Lrrfip1a mRNA level in
shLrrfip1a-1 and shLrrfip1a-2 cells was reduced by 90%
compared to that of the control cell lines on the fifth day after
myoblasts were transferred to the differentiation medium (Fig-
ure 5A, compare lanes 5 and 6 with lane 4). As shown in Fig-
ure 5B, myoblast differentiation is significantly dampened inorts 13, 1647–1657, November 24, 2015 ª2015 The Authors 1651
Figure 5. Lrrfip1a Isoform Is Required for
C2C12 Myoblasts Differentiation
(A) RNAs were extracted from stable cell lines
either expressing shLrrfip1a or shLuci C2C12 cells
before differentiation and after differentiation.
Expression pattern of endogenous Lrrfip1 splicing
isoforms was determined by RT-PCR.
(B) shLrrfip1a and shLuci C2C12 stable cells were
induced to differentiate after switch to low horse
serum medium, and immunostained for MyHC
(green) and DAPI (blue) on the fifth day after
induction.
(C) RNAs were collected from shLrrfip1a or shLuci
C2C12 cells after differentiation for 5 days. Relative
expression levels of skeletal-muscle-differentiated
markers were measured by real-time PCR and
normalized to 36B4.
(D) RNAs were collected as described in (C). Vali-
dation of microarray results by real-time PCR on
three genes predicted from the microarray analysis
was performed.
(E) RNAs were collected from shSRSF10 and
shLuci C2C12 cells after differentiation for 5 days.
Relative expression levels of three genes validated
in (D) were detected by real-time PCR and
normalized to 36B4.
All the values are mean ± SD, n = 3. The signifi-
cance of each detected change was evaluated by
Student’s t test.response to Lrrfip1a knockdown. MyHC-positive cells and fused
myotubes are greatly decreased in both shLrrfip1a myoblasts,
whereas control cells differentiated normally (Figure 5B). Results
of real-time PCR confirmed the greatly attenuated expression of
differentiation markers in the differentiated shLrrfip1a cells (Fig-
ure 5C). Interestingly, knockdown of all endogenous Lrrfip1 iso-
forms produces a phenotype of myoblast differentiation similar
to the specific knockdown of the Lrrfip1a isoform (Figures S5A
and S5B). Meanwhile, re-expression of a murine small interfering
RNA (siRNA)-insensitive Lrrfip1b isoform had no effect on the re-
covery of myogenic defects upon Lrrfip1 knockdown (Figures
S5C and S5D). These findings demonstrate the importance of
Lrrfip1a isoform during the myoblast differentiation.
To explore underlying mechanisms of pro-differentiation ef-
fects of Lrrfip1a, microarray analysis was performed using total
RNA prepared from differentiated shLrrfip1a-2 myoblasts and
control cells. As shown in Table S3, expression levels of genes
such as Id3, Sfrp2, and Nov, which are well-known inhibitors of
muscle differentiation (Anakwe et al., 2003; Melnikova and
Christy, 1996; Sakamoto et al., 2002), were greatly increased.
Real-time RT-PCR further confirmed that both Id3 and Sfrp2
mRNA levels were upregulated more than 3-fold, and levels of
NovmRNA were increased more than 20-fold (Figure 5D). These
results implicate Lrrfip1a as a key regulator of myoblast differen-
tiation, probably by repressing specific differentiation suppres-
sors.Consistentwith the inhibition effects ofLrrfip1a knockdown,
increased expression of these suppressor genes was also
observed in the differentiated shSRSF10 cells (Figure 5E). This
suggested that SRSF10 functions as a regulator for myoblast dif-
ferentiation, possibly by regulatingASevents during this process,
at least through regulating inclusion of Lrrfip1 exons 16 and 17.1652 Cell Reports 13, 1647–1657, November 24, 2015 ª2015 The AuSRSF10 Directly Represses Exon7a Inclusion of PGC1a
We also observed that SRSF10KOmice display severely degen-
erative livers (Feng et al., 2009). We next investigated whether
SRSF10 can regulate AS events in mice primary hepatocytes.
To this end, we constructed adenovirus-mediated shRNA
(Ad-shSRSF10) that was used to knock down expression of
SRSF10 in primary hepatocytes isolated from adult mice. The ef-
ficiency of SRSF10 knockdown was examined by using western
blot (Figure 6A). In addition to the above 16 validated targets, we
redesigned primer pairs that detect alternative exons in another
25 potential transcripts regulated in liver tissues or liver cells and
used these to analyze RNA isolated from control (Ad-shLuci) and
Ad-shSRSF10-infected cells. Although there were no obvious
changes in the splicing patterns of the majority of transcripts
examined (data not shown), three showed significant differ-
ences. Specifically, the inclusion of exon 7a of the pre-mRNA
encoding peroxisome proliferative activated receptor gamma
coactivator 1 alpha (PGC1a, also known as Ppargc1a) was
increased upon SRSF10 knockdown (Figures 6B and 6C). On
the other hand, increased exclusion of Bclaf1 exon 5a and
Ktn1 exon 36 was also observed in the SRSF10-depleted hepa-
tocytes (Figure S6).
Interestingly, according to NCBI gene browser data, inclusion
of PGC1 exon 7a introduces a premature in-frame stop codon
and causes nonsense-mediated decay (Figure 6B). Knockdown
of SRSF10 increases inclusion of exon 7a in PGC1a mRNA (NR
isoform), resulting in decreased expression of the PGC1a NM
isoform, which encodes a functional protein. To determine
whether SRSF10 directly binds to PGC1a exon7a, we performed
gel-shift assays (Figure 6D) and CLIP assays (Figure 6E). The re-
sults demonstrated that SRSF10 strongly binds to exon 7 RNA,thors
Figure 6. SRSF10 Directly Regulates AS of PGC1a pre-mRNA
(A) SRSF10 protein levels were measured in primary hepatocytes infected with Ad-shSRSF10 or Ad-shLuci for 2 days by using western blotting.
(B) Schematic representation of PGC1a splicing isoforms. Primer pairs used for RT-PCR detection were indicated by arrows.
(C) RNAs were extracted from primary hepatocytes infected with Ad-shSRSF10 or Ad-shLuci for two days. Inclusion of PGC1a exon 7a was analyzed using RT-
PCR. Bar graphs show the ratio of inclusion versus exclusion (NR/NM). Values are mean ± SD.
(D) Indicated 32P-labeled PGC1a exon 7 or 7a RNA was incubated with increasing amounts of recombinant His-SRSF10 (100, 200, and 400 ng), and complexes
were resolved by non-denaturing PAGE.
(E) HA-CLIP was performed as described as Figure 4G and analyzed by RT-PCR. Specific primer pairs were designed against mouse PGC1a exon 7 or 7a.
(F) In vitro splicing was performed in HeLa nuclear extracts (NEs) or in HeLa S100 with indicated supplementations using b-globin-E7 or b-globin-E7a RNA.
Products of splicing were analyzed by denaturing PAGE and autoradiography. Splicing products are indicated schematically. The NE lane was a positive control,
while buffer D and S100 were negative controls.but not exon7a RNA, both in vitro and in vivo. Next, we asked
whether SRSF10 regulates PGC1a exon 7a splicing in vitro. To
this end, we constructed and analyzed chimeric b-globin sub-
strates (b-globin-E7 and b-globin-E7a) in which PGC1a exon7
or exon 7a was inserted downstream of the 30 splice site in the
second exon of the b-globin gene (Feng et al., 2008; Li et al.,
2013). Using an S100-based splicing assay (Feng et al., 2008),
splicing of the b-globin-E7 RNA (but not b-globin-E7a RNA)
was greatly enhanced by SRSF10 proteins in a dose-dependent
manner (Figure 6F, compare lanes 5–7 and lanes 12–14). In sum-
mary, SRSF10 binds to exon 7 of PGC1a, activates exon 7
splicing, and represses exon 7a inclusion, and a similar mecha-
nism has been applied for SRSF10 in the regulation of AS of
Lipin1 pre-mRNA (Li et al., 2014) and other AS target transcripts
(Zhou et al., 2014b).
SRSF10 Is Required for GlucoseMetabolism In Vitro and
In Vivo
Overexpression of PGC1a in hepatocytes in culture strongly
activates upregulation of gluconeogenic enzymes, includingCell Repphosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6pase), leading to increased glucose produc-
tion (Yoon et al., 2001). Given that PGC1a is a master regulator
during gluconeogenesis and could be induced upon fasting,
we decided to examine glucose levels in hepatocytes upon
SRSF10 knockdown with or without dexamethasone (Dex)
and forskolin treatment. The addition of Dex and forskolin to
cell cultures has been used to mimic a fasting condition. As
shown in Figure 7A, while there is a slight decrease in glucose
production in response to depletion of SRSF10, this decrease
was greatly amplified following treatment with Dex and forsko-
lin in cells (Figure 7A). Consistent with glucose reduction, we
observed that mRNA levels of the PGC1a NM variant were
not dramatically induced in SRSF10-depleted cells compared
to control cells under treatment (Figure 7B, compare lane 3
with 4; and Figure 7C). Expression of PGC1a downstream
genes, such as PEPCK, G6pase, and Fbp1, was significantly
suppressed (Figure 7B, compare lane 3 with 4; and Figure 7C).
Taken together, these results demonstrate that SRSF10 regu-
lated AS of PGC1a pre-mRNA and is required for glucoseorts 13, 1647–1657, November 24, 2015 ª2015 The Authors 1653
Figure 7. SRSF10 Is Required for Glucose Production Both In Vitro and In Mice
(A) Primary hepatocytes were infected with Ad-shLuci and Ad-shSRSF10 for 2 days in the presence or absence of forskolin and dexamethasone treatment.
Glucose production assay was then performed.
(B and C) mRNA expression level of PGC1a-NM, PEPCK, G6pase, and Fbp1 in cells (A) was measured by RT-PCR and real-time RT-PCR.
(D) Effect of SRSF10 knockdown on blood glucose concentrations relative to control mice in fed and fasted conditions. *p < 0.05, n = 6.
(E) Blood glucose changes in response to pyruvate challenge in mice infected with shLuci and sh-SRSF10 adenovirus. *p < 0.05, **p < 0.01, n = 6.
(F) qPCR analysis of SRSF10, PGC1a-NM, PEPCK, and G6pase gene expression using liver RNA from mice injected with control or sh-SRSF10 adenovirus.
All values are mean ± SD.production in mouse primary hepatocytes, especially under
fasting conditions.
To determine whether knockdown of SRSF10 expression in
livers would affect blood glucose levels in mice, C57BL/6 mice
were injected with Ad-shSRSF10 or control adenovirus through
the tail vein. Significantly, we found that Ad-shSRSF10 infection
reduced glucose levels in mice in both the fed and fasted states
(Figure 7D). In agreement with the mice phenotype, the hepatic
gluconeogenesis was impaired in Ad-shSRSF10 mice as as-
sessed by a pyruvate tolerance test (PTT) (Figure 7E). In line
with the above data, mRNA expression of PGC1a NM and its
downstream gluconeogenicG6pase and PEPCKwas decreased
and could not be elevated by fasting in mice lacking hepatic
SRSF10 (Figure 7F). In summary, these data suggest that
hepatic SRSF10 is indeed required for proper glucose produc-
tion in mice.
DISCUSSION
SRSF10 is a sequence-specific splicing regulator. In this study,
we have provided evidence that SRSF10 regulates AS of several
specific target transcripts and is critically required for muscle
development and glucose production in mice. SRSF10 defi-
ciency leads to deregulated splicing variants and thereby causes1654 Cell Reports 13, 1647–1657, November 24, 2015 ª2015 The Ausevere defects in these processes. Below, we discuss how
SRSF10 functions as an important regulator in many living cells
and organisms by regulating specific AS events.
High-throughput sequencing provides an effective method for
researches to identify AS events in living cells and organisms.
Various targets of splicing regulators were identified by using
RNA-seq, CLIP-seq, or other global profiling approaches (Geh-
man et al., 2012; Pandit et al., 2013; Yang et al., 2014), and
many regulators have been shown to be involved in determina-
tion of cell or tissue type by regulating specific AS events.
SRSF10 is a unique member of the SR protein family. Indeed,
it was initially identified as a general splicing repressor that is
activated by dephosphorylation (Shin et al., 2004; Shin andMan-
ley, 2002). Subsequent experiments have shown that phosphor-
ylated SRSF10 can function as a sequence-dependent splicing
activator (Feng et al., 2008). RNA-seq analysis has identified
various splicing targets of SRSF10 in different cell lines. For
example, SRSF10 controls the inclusion of Bclaf1 exon 5a and
plays a role in colon cancer development (Zhou et al., 2014a).
SRSF10 regulates AS of Lipin1 pre-mRNA and mediates adipo-
genesis (Li et al., 2014).
In this study, we have shown that SRSF10 is required for
myoblast differentiation, muscle development, and gluconeo-
genesis in both isolated hepatocytes and mouse livers. Lrrfip1athors
is prominently expressed in striated muscle and can be induced
during C2C12 myoblast differentiation, and this is consistent
with its significance in myoblast differentiation (see Figures 4
and 5). Mef2a and Fxr1 were identified as another two key
splicing targets of SRSF10 in cardiac and skeletal muscle. Inac-
tivation of Fxr1 has been reported to have drastic effects in
mouse and Xenopus myogenesis (Mientjes et al., 2004; Van’t
Padje et al., 2009). Importantly, its muscle-specific isoform,
which was regulated by SRSF10, was observed to be down-ex-
pressed in facioscapulohumeral muscular dystrophy patients,
implicating that this isoform contributes to the physiopathology
of this disease (Davidovic et al., 2008). Altered expression of
Mef2a splicing isoforms was also observed in myotonic dystro-
phy (Bachinski et al., 2010). Given the biological function of
SRSF10 splicing targets such as Fxr1, Mef2a, and Lrrfip1, in
particular for cardiac development or myoblast differentiation,
it is reasonable to speculate that dysregulated AS is responsible
for the cardiac and skeletal muscle defects of SRSF10 mutant
mice. On the other hand, SRSF10 has no visible effects in regu-
lating AS of Lrrfip1, Fxr1, or Mef2a in primary hepatocytes;
instead, we identified PGC1a as a key splicing target. Consistent
with the role of PGC1a in hepatic glucose production during fast-
ing, we observed that SRSF10 knockdown resulted in decreased
levels of full-length PGC1a mRNA by increasing exon 7a inclu-
sion and concomitantly decreased glucose production after fast-
ing. In summary, all findings demonstrate that SRSF10 functions
as an important regulator inmultiple biological processes, mainly
by regulating specific and distinct splicing in a cell-context-
dependent manner.
Aside from cell-specific AS events, comparison of validated
splicing regulated by SRSF10 in murine ventricles, C2C12 cells,
and hepatocytes revealed that transcripts of Acly, Axin1, Bclaf1,
or Ktn1 show cell-type, non-specific splicing changes. Bclaf1 is
an extremely conserved protein, and it shares 96% and 91%
amino acid identity between mouse and human and between
chicken and human, respectively (Zhou et al., 2014a). Not sur-
prisingly, inclusion of Bclaf1 exon 5a was observed to be
controlled by SRSF10 in all the cells lines examined in our lab,
including chicken DT40 cells, human cancer cell lines, and mu-
rine cell lines. However, isoform-specific knockdown of Bclaf1
exon 5a has no effect on mouse embryonic fibroblast differenti-
ation, C2C12 differentiation, or DT40 stress-related defects (data
not shown), although it plays an important role in tumorigenesis
(Zhou et al., 2014a). This likely reflects cell-context-dependent
functions by Bclaf1, or rather this reflects the complexity of
splicing control in vivo, which still remains elusive. In addition,
we observed in our previous studies that knockdown of individ-
ual splicing targets of SRSF10 could not mimic the ER-stress-
related defects caused by SRSF10 depletion in DT40 cells.
However, reconstituted SRSF10 in DT40 KO cells could recover
the WT splicing patterns for the majority of SRSF10-verified
splicing events and considerably rescued stress-related defects
(Zhou et al., 2014b). It is thus possible that a combination of cell-
specific AS events and non-specific AS events contributes to the
differential effects of SRSF10 in vivo.
Skeletal muscle is one of the tissues showing the highest num-
ber of tissue-specific exons (Castle et al., 2008). However, SR
proteins have not been investigated in skeletal muscle develop-Cell Repment, as the focus has mainly been placed on other splicing
regulators, such as the CELF, FOX, and hnRNP families (Llorian
and Smith, 2011). In this study, we have shown that SRSF10
regulates muscle-specific splicing and is required for skeletal
muscle development. Interestingly, RBM24, like SRSF10, regu-
lates splicing of the Fxr1 pre-mRNA (Yang et al., 2014). Our
results suggest a possible interplay involving SRSF10 and
other splicing regulators in AS control. Since most AS events
are likely subjected to regulation by multiple different splicing
regulators, which may act synergistically or antagonistically, it
will thus be of interest to determine how the regulatory network
involving SRSF10 and other splicing regulators function in
myogenesis.
In summary, loss of SRSF10 impairs striated muscle develop-
ment, myoblast differentiation, and glucose production both in
isolated hepatocytes and in mice. Using RNA-seq analysis, we
identified cell-type-specific AS events and non-specific splicing
events. By understanding how SRSF10 modulates AS of cell-
type-endogenous transcripts, we have moved closer toward
elucidating the role of AS as an important modifier inmultiple bio-
logical processes.
EXPERIMENTAL PROCEDURES
RNA-Seq, Data Analysis, and Pathway Enrichment Analysis
Total RNA isolated fromWT or KO ventricles of E13.5 embryos was subjected
to paired-end RNA-seq using the Illumina HiSeq 2000 system according to the
manufacturer’s instructions. Read mapping and data analysis for differentially
regulated exons between two samples were carried out as previously
described (Zhou et al., 2014b). In brief, reads were mapped to a reference
mouse genome and transcriptome using TopHat. Data analysis was carried
out using ASD software to detect the differentially regulated exons between
the two samples. To identify the significantly changed alternative splicing
events, a Fisher’s exact test was performed for each event using a 2 3 2
contingency table consisting of the read counts from either the inclusion or
exclusion isoforms in the two samples. Functional enrichment analysis of
regulated AS genes was performed using DAVID online tools (https://david.
ncifcrf.gov/home.jsp). The level of significance was set at p < 0.05 (Fisher’s
exact test).
Mice and Histological Analysis
SRSF10 heterozygous mouse were kindly provided by Dr. Manley (Columbia
University) and mated as previously described (Feng et al., 2009). Embryos
were removed from the pregnant mouse at E18.5 and fixed in 4% paraformal-
dehyde overnight at 4C. Transverse sections of hindlimbs were cut and
embedded in paraffin and stained with H&E. Experiments involving the use
of animals were approved by the Institutional Animal Care and Use Committee
of Institute for Nutritional Sciences.
Cell Culture and Differentiation
C2C12 myoblasts were grown in DMEM medium containing 10% fetal bovine
serum and 1% penicillin/streptomycin antibiotics. To induce differentiation,
cells were switched to media containing DMEM with 2% horse serum and
1% penicillin/streptomycin antibiotics at 95% confluence.
Isolation of Primary Hepatocytes
Primary hepatocytes were prepared by collagenase perfusion as described
previously (Shao et al., 2014). In brief, male C57BL/6J mice at 10 weeks of
age were anesthetized, and collagenase perfusion was performed. The liver
was aseptically removed to a sterile 10-cm cell culture dish with 20 ml ice-
cold perfusion buffer without collagenase. The excised liver was cut and hepa-
tocytes were dispersed followed by filtration and centrifugation. Cells were
then washed and re-suspended in HepatoZYME-SFM (GIBCO) mediumorts 13, 1647–1657, November 24, 2015 ª2015 The Authors 1655
supplemented with 2 mM L-glutamine, 20 U/ml penicillin, and 20 mg/ml strep-
tomycin. After determining viability using trypan blue staining, hepatocytes
were plated at 6 3 105 cells per well in six-well culture dishes that were pre-
coated with collagen.
Mice and Pyruvate Tolerance Tests
Eight-week-old C57BL/6J mice were housed in colony cages with 12-hr
light-dark cycles before use. Recombinant adenovirus (0.5 3 109 PFU) was
delivered to mice via tail-vein injection. To measure fasting blood glucose,
the mice were fasted for 12 hr (but allowed free access to water). For the
pyruvate tolerance test (PTT) assay, overnight-fasted mice infected with
Ad-shSRSF10 or control adenovirus each received an intraperitoneal injec-
tion of 2 g/kg sodium pyruvate dissolved in PBS. Tail-vein blood samples
were assessed for glucose concentration immediately before injection
(time 0) and at 15, 30, 60, 90, and 120 min after injection. Liver RNA was
then pooled for real-time PCR analysis. All procedures were approved by
the Institution for Nutritional Sciences Institutional Animal Care and Use
Committee, Shanghai Institutes for Biological Sciences, Chinese Academy
of Sciences, China.
Adenovirus Infection and Glucose Production Assay
In brief, primary hepatocytes were cultured for 8 hr followed by infection with
Ad-shSRSF10 or control Ad-shLuci adenovirus for 2 days. Then, the medium
was switched to glucose- and phenol-free DMEM (pH 7.4) containing 20 mM
sodium lactate and 2 mM sodium pyruvate supplemented with or without
100 nM dexamethasone and 10 mM forskolin. After 12 hr, 500 ml medium
was collected, and the glucose content was measured using a colorimetric
glucose assay kit (Sigma-Aldrich). The readings were then normalized to the
total protein amount in the whole-cell lysates.
Statistical Analysis
All data presented as histograms represent mean ±SD values of the total num-
ber of independent experiments. Statistical analysis was performed using the
Student’s t test at a significance level of p < 0.05. Quantification of western
blots and RT-PCR was done using ImageJ software (version 1.43u).
Details of other methods are presented in the Supplemental Experimental
Procedures.
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